| Excerpt | Reference |
|---|
| "Nine patients with ocular hypertension receiving treatment with timolol were entered into the study." | ( Batterbury, M; Harding, SP; Wong, D, 1992) |
| "In 12 patients with ocular hypertension and similar pressures in each eye, one eye was randomly selected in a masked manner for pretreatment with three applications of topical 0." | ( Bealka, N; Schwartz, B, 1991) |
| "A patient with ocular hypertension was treated with acetazolamide." | ( Jondeau, G; Kanfer, A; Mougenot, B; Ronco, P; Rondeau, E; Rossert, J; Sraer, JD, 1989) |
| "One half of 20 patients (40 eyes) with ocular hypertension and occludable angles, some with peripheral anterior synechiae, were randomly assigned for treatment by Nd:YAG laser iridotomy." | ( Hitchings, RA; Pooinasawmy, D; Romano, JH, 1988) |
| "Ten patients with glaucoma or ocular hypertension (totally 15 pathological eyes and 5 healthy) who had had topical timolol for at least 2 months received the coded oral treatment." | ( Kättström, O; Ohrström, A, 1983) |
| "In 25 patients with ocular hypertension and open angles timolol maleate lowered the intraocular pressure (IOP) of 71% of the 49 eyes treated, keeping it below 22 mm Hg during 4 years of therapy." | ( Markowitz, S; Morin, JD, 1983) |
| "These results indicate that, in treated ocular hypertension, pattern electroretinogram losses tend to be associated with moderately increased intraocular pressures in the range of 21-25 mm Hg." | ( Buzzonetti, L; Colotto, A; Coppè, A; De Luca, LA; Falsini, B; Giudiceandrea, A; Salgarello, T, 1995) |
| "In 12 patients with untreated ocular hypertension and similar intraocular pressures in each eye, one eye was randomly selected in a masked manner for pretreatment with three applications of topical 0." | ( Bealka, N; Rom, M; Schwartz, B, 1997) |
| "Patients with ocular hypertension or glaucoma were topically treated with latanoprost 50 micrograms/ml once daily for 6-12 months." | ( Alm, A; Lindén, C; Nuija, E, 1997) |
| "Fifty patients with glaucoma or ocular hypertension were treated in a randomized, crossover, double-masked fashion with 1 drop of latanoprost (50 microg/ml once daily and 15 microg/ml twice daily) in the affected eye(s) for 3 weeks on each concentration." | ( Glovinsky, J; Lusky, M; Melamed, S; Nesher, R; Ticho, U; Weinberger, D; Yassur, Y, 1997) |
| "20 patients with open angle glaucoma or ocular hypertension and an elevated intraocular pressure (IOP) over 21 mmHg and without prior oral CAI-treatment were included in this study." | ( Barisani, T; Baumgartner, I; Biowski, R; Hommer, A; Kaminski, S; Koyuncu, D, 1998) |
| "In patients with ocular hypertension or chronic open-angle glaucoma treated with beta-blockers for at least three months, we prescribed timolol maleate solution 0." | ( Cate, EA; Mundorf, TK; Otero, DW; Sine, CS; Stewart, JA; Stewart, WC, 1998) |
| "In the group of rabbits with ocular hypertension having taken verapamil treatment, the Ca+2 content was markedly lower, the changes of mitochondria milder and the Ca+2 deposition in mitochondria less than that of the ocular hypertension group without treatment." | ( Cheng, D; Ji, J; Sun, W, 1996) |
| "Thirty patients with ocular hypertension or early capsular or primary open-angle glaucoma and elevated IOP were randomly assigned to two parallel treatment groups." | ( Güler, C; Kimal Arici, M; Topalkara, A, 1998) |
| "Many patients with glaucoma or ocular hypertension initially receive beta-blocker monotherapy to control intraocular pressure (IOP), but some of these patients will require an additional IOP-lowering agent within 1 year." | ( Gormley, GJ; Hartenbaum, D; Liss, C; Maloney, S; Vaccarelli, L; Wilson, H, 1999) |
| "Eight persons with ocular hypertension were treated with the methazolamide-cyclodextrin eye drops and eight persons with dorzolamide (Trusopt), both groups at dosages of three times a day for 1 week." | ( Bjarnadóttir, G; Gudmundsdóttir, E; Gudmundsdóttir, G; Loftsson, T; Masson, M; Sigurjónsdóttir, JF; Stefánsson, E, 2000) |
| "Twenty-nine patients with glaucoma or ocular hypertension were imaged using the Heidelberg Retina Tomograph before and after the administration of latanoprost to decrease intraocular pressure." | ( Bowd, C; Emdadi, A; Lee, B; Weinreb, RN; Zangwill, LM, 2000) |
| "Reproducible and reversible ocular hypertension was induced in approximately 40% of the monkeys treated with DEX, similar to that seen in man." | ( Alward, WL; Clark, AF; Craig, JE; Fingert, JH; Mackey, DA; McLaughlin, M; Sheffield, VC; Snibson, GR; Stone, EM; Tuttle, L, 2001) |
| "Inhalation steroid therapy can cause ocular hypertension or open angle glaucoma." | ( Casteels, I; Casteels, K; Desnoeck, M, 2001) |
| "Ninety patients with untreated ocular hypertension, defined as elevated intraocular pressure and normal visual fields, were randomly assigned to treatment and prospectively observed at 3-month intervals for up to 10 years in a double-masked fashion." | ( Bengtsson, B; Heijl, A, 2001) |
| "In treating patients with ocular hypertension or primary open-angle glaucoma, if a single agent cannot successfully control the pressure, additional medications may be prescribed." | ( Day, DG; Ellyn, J; Kulze, J; Leech, J; Sharpe, ED; Stewart, WC, 2002) |
| "Patients with ocular hypertension and/or primary open-angle glaucoma who had not responded to or could not tolerate beta-blocker therapy." | ( Berdeaux, G; Berto, P; Gouveia Pinto, C; Le Pen, C; Rouland, JF, 2003) |
| "Primary open-angle glaucoma or ocular hypertension patients were randomly assigned to one of the treatment groups for a 6-week treatment period and then crossed over to the opposite treatment." | ( Day, DG; Leech, J; Schacknow, PN; Sharpe, ED; Stewart, JA; Stewart, WC; Wand, M, 2003) |
| "Twenty cases(40 eyes) with ocular hypertension or primary open angle glaucoma(POAG) in early stage were treated by 4% PG(once per night) and PS(4 times per day)." | ( Chen, X; Liang, L; Yie, T, 2000) |
| "Patients with glaucoma or ocular hypertension who needed additional IOP lowering or who were intolerant of other glaucoma medications were placed on bimatoprost therapy (alone or in combination with other drugs at the physician's discretion)." | ( Bournias, TE; Gross, R; Lee, D; Mattox, C, 2003) |
| "Thirty patients with untreated ocular hypertension or primary open-angle glaucoma (mean age: 59." | ( Babighian, S; Bonadimani, M; Ghilotti, G; Marchini, G, 2003) |
| "In the monkey model, ocular hypertension and morphological optic nerve damage were shown by laser-treated eyes." | ( Hara, H; Shimazawa, M; Taniguchi, T, 2004) |
| "to report a case of severe ocular hypertension occurring as a complication after a single intravitreal injection of triamcinolone acetonide for the treatment of a diabetic cystoid macular edema." | ( Detry-Morel, M; Escarmelle, A; Hermans, I, 2004) |
| "Eighteen patients with ocular hypertension or early glaucomatous changes (aged 41 to 79 years) each received topical treatments with timolol (0." | ( Kripke, DF; Liu, JH; Weinreb, RN, 2004) |
| "Tonometry led to the diagnosis of ocular hypertension induced by the steroid therapy." | ( Alén Cordero, R; Bilbao-Calabuig, R; Calvo Arrabal, MA; Llovet Osuna, F, 2005) |
| "Glaucoma or ocular hypertension patients receiving a combined treatment of timolol 0." | ( Avila, MP; Magacho, L; Reis, R; Santos, LC; Shetty, RK, 2006) |
| "A subanalysis of patients with ocular hypertension who were previously treated on latanoprost monotherapy and continued within the study on this same medication for at least 6 months." | ( Christ, T; Hofstetter, HJ; Schnober, D; Stewart, WC; Thelen, U, 2007) |
| "353 patients with ocular hypertension were included and treated with latanoprost monotherapy historically (1." | ( Christ, T; Hofstetter, HJ; Schnober, D; Stewart, WC; Thelen, U, 2007) |
| "The study suggests that patients with ocular hypertension already treated with latanoprost monotherapy will continue to have, on average, at least midterm stable pressures, low incidence of side effects and discontinuations, as well as "very good" to "excellent" physician ratings of efficacy, tolerability, and patient satisfaction." | ( Christ, T; Hofstetter, HJ; Schnober, D; Stewart, WC; Thelen, U, 2007) |
| "In certain patients with glaucoma and ocular hypertension brimonidine may be a better choice than dorzolamide for second-line treatment." | ( Craven, ER; Katz, LJ; Simmons, ST, 2007) |
| "In a chronic model of ocular hypertension, we examined the efficacy of acute topical administration of WIN55212-2 (WIN) in a novel commercially available vehicle and in combination with timolol." | ( Allen, RC; Castillo, IG; Hosseini, A; Lattanzio, FA; Lichtman, AH; Oltmanns, MH; Samudre, SS; Williams, PB, 2008) |
| "Patients had open-angle glaucoma or ocular hypertension and were randomized to twice-daily therapy with either brinzolamide 1%/timolol 0." | ( Evans, RM; Mallick, S; Stewart, RH; Vold, SD; Walters, T, 2008) |
| "Use of a risk calculator in cases of ocular hypertension changed treatment recommendations." | ( Boland, MV; Lehmann, HP; Quigley, HA, 2008) |
| "Patients with ocular hypertension or glaucoma who received first-line treatment with either travoprost or latanoprost/timolol and were followed up for >6 months were included." | ( Berdeaux, G; De Natale, R; Lafuma, A, 2009) |
| "Twenty-six patients with glaucoma or ocular hypertension (ages, 44-79 years) who were receiving treatment with 0." | ( Liu, JH; Medeiros, FA; Slight, JR; Weinreb, RN, 2009) |
| "In addition, in the rabbit ocular hypertension model, the topical administration of H-1152P (28 mM) significantly lowered IOPs starting at 30 minutes and lasting up to 300 minutes after water loading." | ( Fukunaga, T; Hidaka, H; Ikesugi, K; Nishio, M; Sugimoto, M; Sumi, K; Uji, Y, 2009) |
| "In patients with open-angle glaucoma or ocular hypertension, long-term treatment (for up to 48 months) with once-daily bimatoprost 0." | ( Curran, MP, 2009) |
| "The treatments of glaucoma or ocular hypertension are associated with numerous ocular surface changes." | ( Baudouin, C; Labbé, A, 2010) |
| "In the second part, the ocular hypertension model was induced unilaterally in the rats by a diode laser treatment." | ( Huang, P; Li, H; Liu, J; Tang, Y; Wei, R; Xu, Y; Zhang, C; Zhang, SS, 2011) |
| "To determine the cost-effectiveness of ocular hypertension (OH) treatment initiated with latanoprost compared to timolol." | ( Hendrikse, F; Peeters, A; Prins, MH; Schouten, JS; Severens, JL; Webers, CA, 2012) |
| "Patients with untreated OAG or ocular hypertension received DT for 12 weeks to reduce intraocular pressure (IOP)." | ( Bastien, NR; Behki, R; Boucher, S; Crichton, AC; Harasymowycz, P; Hutnik, CM; Ibrahim, F; Liao, C; Rifkind, AW; Sampalis, JS; Solomon, L, 2010) |
| "In an animal model of ocular hypertension, one of the new compounds was twice more effective than dorzolamide in reducing elevated intraocular pressure characteristic of this disease, anticipating their potential for the treatment of glaucoma." | ( Benedini, F; Biondi, S; Cecchi, A; Formicola, G; Masini, E; Mincione, F; Pacileo, I; Scozzafava, A; Supuran, CT; Temperini, C, 2011) |
| "Patients with glaucoma or ocular hypertension who required a change of medication or were naïve to treatment were included in this noninterventional and observational study." | ( Erb, C; Kimmich, F; Lanzl, I; Seidova, SF, 2011) |
| "Patients with glaucoma or ocular hypertension who do not achieve target intraocular pressure (IOP) using one hypotensive agent are often transitioned to combination therapy." | ( Liehneova, I; Negrete, FJ; Scherzer, ML; Schnober, D, 2011) |
| "Twenty-eight untreated patients with ocular hypertension were recruited." | ( De Bacquer, D; Kestelyn, PA; Kestelyn, PG; Stevens, AM, 2012) |
| "Patients with open-angle glaucoma or ocular hypertension who had been treated with BAK-preserved latanoprost 0." | ( Aihara, M; Araie, M; Oshima, H, 2013) |
| "Patients had open-angle glaucoma or ocular hypertension, which could not be controlled with monotherapy and were randomized to twice daily therapy with either brinzolamide 1%/timolol 0." | ( Akçali, G; Bozkurt, KT; Güney, E; Sezgin Akçay, Bİ; Unlü, C, 2013) |
| "Improving adherence to ocular hypertension (OH)/glaucoma therapy is highly likely to prevent or reduce progression of optic nerve damage." | ( Bhattacharya, D; Broadway, DC; Cate, H; Clark, A; Fordham, R; Holland, R, 2014) |
| "One hour after ocular hypertension (OH), SNJ-1945 was administrated as a single oral dose of 50 mg/kg." | ( Azuma, M; Oka, T; Shearer, TR; Suzuki, R; Tamada, Y, 2014) |
| "In the present model of ocular hypertension (OHT), we have recently described morphological signs of retinal microglia activation and MHC-II upregulation in both the untreated contralateral eyes and OHT eyes." | ( Avilés-Trigueros, M; de Hoz, R; Gallego, BI; Ramírez, AI; Ramírez, JM; Rojas, B; Salazar, JJ; Triviño, A; Valiente-Soriano, FJ; Vidal-Sanz, M; Villegas-Perez, MP, 2014) |
| "To review the literature regarding ocular hypertension following intravitreal antivascular endothelial growth factor therapy, and to propose a novel mechanism for the development of ocular hypertension as a result of such therapy." | ( Morshedi, RG; Ricca, AM; Wirostko, BM, 2016) |
| "Sustained ocular hypertension following the intravitreal administration of antivascular endothelial growth factor agents is a potentially serious side effect that has not been adequately explained." | ( Morshedi, RG; Ricca, AM; Wirostko, BM, 2016) |
| "In vehicle-treated animals, ocular hypertension resulted in a 29." | ( Alsarraf, O; Chou, CJ; Crosson, CE; Dahrouj, M; Fan, J; Yates, PW, 2014) |
| "200 patients with glaucoma or ocular hypertension, controlled on the unfixed combination of latanoprost and timolol or eligible for dual therapy being not being fully controlled on monotherapy were enrolled in a randomized, double-masked, placebo-controlled, multicentre clinical trial." | ( Boehm, A; Centofanti, M; Fogagnolo, P; Goldblum, D; Karabatsas, CH; Rossetti, L; Sacchi, M; Topouzis, F; Vetrugno, M; Vorwerk, C, 2015) |
| "The pathophysiology of ocular hypertension (OH) leading to primary open-angle glaucoma shares many features with a secondary form of OH caused by treatment with glucocorticoids, but also exhibits distinct differences." | ( Allayee, H; Argüeso, P; Avery, RL; Coetzee, GA; Conti, DV; Davis, JL; Eaton, AM; Edlund, CK; Fini, ME; Flynn, HW; Gao, X; Hartiala, J; Hazelett, DJ; Hijikata, M; Itakura, T; Jeong, S; Keicho, N; Lalwani, G; Patel, N; Pletcher, MT; Puliafito, CA; Schwartz, SG; Wafapoor, H; Wu, PC, 2015) |
| "Patients with open-angle glaucoma or ocular hypertension who received XALATAN monotherapy for at least 3 months and had SPK in both eyes were enrolled at 9 facilities." | ( Aihara, M; Arakaki, Y; Ikeda, Y; Kita, N; Kobayashi, S; Mizoue, S, 2016) |
| "Inclusion criteria were ocular hypertension (OHT) or open-angle glaucoma (OAG) with a maximum intraocular pressure (IOP) of 21 mmHg on a preserved prostaglandin monotherapy." | ( Cordeiro, MF; Hommer, A; Montesano, G; Oddone, F; Ribeiro, L; Rossetti, L; Stalmans, I; Sunaric-Mégevand, G, 2016) |
| "Patients with open-angle glaucoma and ocular hypertension treated with SLT have significantly reduced peak IOPs and fluctuation in IOP in response to the WDT." | ( Kerr, NM; Lew, HR; Skalicky, SE, 2016) |
| "Episodes of ocular hypertension after Ozurdex implant were generally transient and successfully managed with topical treatment." | ( Agard, É; Bellocq, D; Denis, P; Dot, C; Kodjikian, L; Malclès, A; Vié, AL; Voirin, N, 2017) |
| "To evaluate ocular hypertension (OHT) after Ozurdex injection to determine the incidence of OHT, therapy for OHT, and any associative factors such as diagnosis, underlying glaucoma and therapy, or sequential Ozurdex injection(s)." | ( Almeida, DRP; Boldt, HC; Chin, EK; Corbella, M; Elshatory, YM; Folk, JC; Gehrs, KM; Kwon, YH; Mahajan, VB; Peraire, M; Russell, SR; Sohn, EH; Velez, G; Xu, K, 2017) |
| "Glucocorticoid (GC)-induced ocular hypertension (OHT) is a serious adverse effect of prolonged GC therapy that can lead to iatrogenic glaucoma and permanent vision loss." | ( Clark, AF; Kasetti, RB; Maddineni, P; Millar, JC; Patel, GC; Phan, TN; Zode, GS, 2017) |
| "To analyze the prognostic factors for ocular hypertension after posterior subtenon injection of triamcinolone acetonide (PSTA) for the treatment of diabetic macular edema (DME)." | ( Chang, SH; Hsieh, YT; Yang, CM, 2017) |
| "Patients with glaucoma or ocular hypertension who initiated tafluprost treatment were registered and prospectively observed over a 2-year period in the real-world setting in Japan." | ( Hashimoto, M; Kakegawa, R; Kuwayama, Y; Nomura, A; Shimada, F, 2017) |
| "A pre-teen with septic CST leading to ocular hypertension and acute visual loss was treated at our institution with thrombectomy and thrombolysis of the cavernous sinuses and superior ophthalmic veins." | ( Bauer, J; Chao, KH; Feng, L; Kansagra, K, 2018) |
| "A pre-teen with septic CST leading to ocular hypertension and acute visual loss was treated at our institution with thrombectomy and thrombolysis of the cavernous sinuses and superior ophthalmic veins." | ( Bauer, J; Chao, KH; Feng, L; Kansagra, K, 2018) |
| "Steroid-induced ocular hypertension (SIOH) is a challenging entity in paediatric age, with many being refractory to medical therapy." | ( Abegão Pinto, L; Leal, I; Sousa, DC, 2018) |
| "A total of 140 patients with glaucoma or ocular hypertension controlled with benzalkonium chloride-latanoprost for at least 3 months were switched to treatment with preservative-free latanoprost." | ( Baudouin, C; Kinasz, R; Lubinski, W; Misiuk-Hojlo, M; Mocko, L; Mulak, M; Ortyl-Markiewicz, R; Podboraczynska-Jodko, K; Pomorska, M; Prost, M; Rekas, M; Rokicki, D; Romaniuk, W; Wasyluk, J; Wierzbowska, J; Zaleska-Zmijewska, A, 2019) |
| "Twenty-seven patients with ocular hypertension (OHTN) or open angle glaucoma who were receiving stable monotherapy with a PGA were admitted to an inpatient sleep laboratory for 24-h monitoring of IOP, blood pressure (BP), and heart rate over 2 separate visits." | ( Kahook, MY; Lynch, AM; Seibold, LK; Wagner, BD, 2018) |
| "Incidence of ocular hypertension after 2-mg IVT compares favorably with other intravitreally administered corticosteroids." | ( Borkar, D; Goodman, J; Obeid, A; Pancholy, M; Regillo, C; Storey, PP; Su, D, 2020) |
| "He was diagnosed with ocular hypertension (OHT) and the management plan was for monitoring without treatment." | ( Habib, SN; Lin, Z; Puvanachandra, N, 2019) |
| "She developed severe ocular hypertension (intraocular pressures (IOPs) of 54 mm Hg in the right eye and 61 mm Hg in the left eye) requiring inpatient therapy with intravenous acetazolamide." | ( Beverstock, A; Kelly, A, 2019) |
| "New open-angle glaucoma (OAG) and ocular hypertension (OHT) therapies that reduce treatment burden and improve outcomes relative to currently available agents are needed." | ( Asrani, S; Bacharach, J; Heah, T; Holland, E; Kopczynski, CC; Lewis, RA; McKee, H; Sheng, H, 2020) |
| "The acute ocular hypertension animal model was induced by the perfusion of normal saline solution into anterior chamber of eyes to elevate the intraocular pressure (IOP) to 110 mmHg for 60 min in the rats of the carnosic-acid-treated group and hypertensive group." | ( Chen, B; He, L; Liang, L; Xiao, C; Zhu, M, 2020) |
| "Subjects with untreated ocular hypertension (n = 30; mean age 67 ± 8 years; 14 females) underwent ophthalmologic examination and a 3-Tesla magnetic resonance imaging investigation." | ( Ambarki, K; Eklund, A; Hallberg, P; Jóhannesson, G; Lindén, C; Qvarlander, S; Wåhlin, A, 2020) |
| "Steroid-induced ocular hypertension (OHT) occurs in about a third of cases after dexamethasone implant (DEXi) intravitreal injection (IVI), for which treatment discontinuation may be required." | ( Agard, E; Billant, J; Brunet, O; Dot, C; Douma, I; Levron, A; Remignon, CH; Sejournet, L, 2022) |